Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.

Alexandra CharrowFan Di XiaJessica LuMichael WaulCara JoyceArash Mostaghimi

Published in: PloS one (2019)

iPLEDGE may disproportionately contribute to access barriers for non-white patients. Continued evaluation of iPLEDGE is needed to minimize unintended barriers to access.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported